Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 9/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ESRRA | P11474 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048209 | 0.84 | AR (0.47) | IDO1AR | |
| SCHEMBL7041988 | 0.81 | AR (0.43) | AR | |
| SCHEMBL7040375 | 0.79 | IDO1 (0.41) | IDO1ARP2RY1LTA4HPTGS2 | |
| SCHEMBL7044482 | 0.79 | L3MBTL1 (0.40) | ARP2RY1 | |
| SCHEMBL7043417 | 0.78 | HPGD (0.49) | LTA4HPTGS2 | |
| SCHEMBL7044751 | 0.77 | ALDH1A1 (0.46) | IDO1P2RY1 | |
| SCHEMBL25005710 | 0.76 | TRPV4 (0.37) | ARPTGS2 | |
| SCHEMBL7041843 | 0.75 | RXRA (0.51) | IDO1 | |
| SCHEMBL25764568 | 0.75 | LMNA (0.43) | ARCYP3A4 | |
| SCHEMBL1685381 | 0.74 | LTA4H (0.46) | IDO1P2RY1LTA4HPTGS2MRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660755-B2 | Controlling cell proliferation agent; skin disorders; antiinflamamtory agents | ALLERGAN, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030109687-A1 | Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity | ALLERGAN, INC. | 2003-06-12 | — | — | US | disclosed |
| US-6455701-B1 | SUCH AS 4-((4'-TERT-BUTYL-3'-(4?-TRIFLUOROMETHYL)PHENOXY) PHENYLETHYNYL)BENZOIC ACID; SIDE EFFECT REDUCTION | ALLERGAN, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6187950-B1 | A REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES | ALLERGAN, INC. | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109687-A1 | Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity | RXRB, RXRA, RXRG | IDO1 3174/4885AR 67/4885P2RY1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.